MCID: MCN008
MIFTS: 43

Mucinous Cystadenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Mucinous Cystadenocarcinoma

MalaCards integrated aliases for Mucinous Cystadenocarcinoma:

Name: Mucinous Cystadenocarcinoma 12 15
Cystadenocarcinoma, Mucinous 44 73
Pseudomucinous Cystadenocarcinoma 12
Cystadenocarcinoma Mucinous 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3603
MeSH 44 D018282
NCIt 50 C3776
SNOMED-CT 68 79143006
UMLS 73 C0206699

Summaries for Mucinous Cystadenocarcinoma

Disease Ontology : 12 A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue, with a capsulated structure and mucus-producing cells.

MalaCards based summary : Mucinous Cystadenocarcinoma, also known as cystadenocarcinoma, mucinous, is related to ovarian mucinous cystadenocarcinoma and cystadenocarcinoma. An important gene associated with Mucinous Cystadenocarcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are CLEC7A (Dectin-1) signaling and O-linked glycosylation. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include pancreas, ovary and appendix, and related phenotype is Reduced mammosphere formation.

Wikipedia : 76 Mucinous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma... more...

Related Diseases for Mucinous Cystadenocarcinoma

Diseases related to Mucinous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 231)
# Related Disease Score Top Affiliating Genes
1 ovarian mucinous cystadenocarcinoma 33.7 FSHR PCNA VIM
2 cystadenocarcinoma 31.6 KRT7 MUC1 MUC16 MUC2
3 giant cell tumor 30.7 MUC1 PTPRC VIM
4 krukenberg carcinoma 30.4 KRT20 KRT7
5 cystic teratoma 30.4 KRT20 KRT7 MUC2
6 pseudomyxoma peritonei 30.4 KRT20 KRT7 MUC1 MUC2
7 endodermal sinus tumor 30.2 MUC16 VIM
8 mucinous ovarian cystadenoma 30.1 KRT7 MUC1
9 cystadenoma 30.0 KRT20 KRT7 MUC1 MUC2
10 ovarian brenner tumor 30.0 KRT20 KRT7 MUC16
11 small cell carcinoma 29.8 KRT20 KRT7 PTPRC
12 dermoid cyst 29.7 KRT20 KRT7 MUC1 VIM
13 ovarian cancer 29.4 FSHR KRT7 MUC1 MUC16 MUC2
14 lung mucinous cystadenocarcinoma 12.5
15 mucinous cystadenocarcinoma of the pancreas 12.4
16 appendix mucinous cystadenocarcinoma 12.2
17 breast mucinous cystadenocarcinoma 12.2
18 pancreatic non-invasive mucinous cystadenocarcinoma 12.2
19 pancreatic invasive mucinous cystadenocarcinoma 12.2
20 pancreatic colloid cystadenocarcinoma 11.2
21 gelatinous ascites 10.5
22 teratoma 10.4
23 sarcoma 10.4
24 hemangiopericytoma, malignant 10.3 MUC1 VIM
25 osteofibrous dysplasia 10.3 MUC1 VIM
26 chondroid chordoma 10.3 MUC1 VIM
27 perineurioma 10.3 MUC1 VIM
28 optic nerve glioma 10.3 MUC1 VIM
29 cerebral primitive neuroectodermal tumor 10.3 MUC1 VIM
30 fasciitis 10.3 MUC1 VIM
31 polymorphous low-grade adenocarcinoma 10.3 MUC1 VIM
32 myoepithelioma 10.3 PTPRC VIM
33 reticulosarcoma 10.3 MUC1 PTPRC
34 plasmablastic lymphoma 10.3 MUC1 PTPRC
35 fibrolamellar carcinoma 10.3 KRT7 VIM
36 granulosa cell tumor of the ovary 10.3 KRT7 VIM
37 pulmonary hemosiderosis 10.2 KRT7 MUC1
38 malignant ovarian surface epithelial-stromal neoplasm 10.2 KRT7 MUC1
39 ovary epithelial cancer 10.2 KRT7 MUC1
40 sertoli-leydig cell tumor 10.2 KRT7 MUC1
41 intraneural perineurioma 10.2 KRT7 MUC1
42 sclerosing hemangioma 10.2 KRT7 MUC1
43 lipoadenoma 10.2 KRT7 MUC1
44 syringoma 10.2 MUC1 VIM
45 malignant peritoneal mesothelioma 10.2 MUC1 VIM
46 primitive neuroectodermal tumor of the cervix uteri 10.2 PTPRC VIM
47 papillary tumor of the pineal region 10.2 MUC1 VIM
48 syringocystadenoma papilliferum 10.2 MUC1 VIM
49 ossifying fibromyxoid tumor 10.2 MUC1 VIM
50 multicentric reticulohistiocytosis 10.2 PTPRC VIM

Graphical network of the top 20 diseases related to Mucinous Cystadenocarcinoma:



Diseases related to Mucinous Cystadenocarcinoma

Symptoms & Phenotypes for Mucinous Cystadenocarcinoma

GenomeRNAi Phenotypes related to Mucinous Cystadenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.02 FSHR KRT7 PCNA PTPRC VIM

Drugs & Therapeutics for Mucinous Cystadenocarcinoma

Drugs for Mucinous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
3
Bevacizumab Approved, Investigational Phase 3,Phase 1 216974-75-3
4
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
6
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
7
Oxaliplatin Approved, Investigational Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
8
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Not Applicable 59-30-3 6037
10 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
11 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
12 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
13 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
14 Angiogenesis Inhibitors Phase 3,Phase 1
15 Angiogenesis Modulating Agents Phase 3,Phase 1
16 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
17 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
18 Immunoglobulins Phase 3,Phase 2,Phase 1
19 Antibodies Phase 3,Phase 2,Phase 1
20 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
21 Antirheumatic Agents Phase 3,Phase 2,Phase 1
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
23 Alkylating Agents Phase 3,Phase 2,Phase 1
24 Antimetabolites Phase 3,Phase 2,Phase 1
25 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
26 Immunoglobulin G Phase 3,Phase 1
27 Endothelial Growth Factors Phase 3,Phase 1
28 Mitogens Phase 3,Phase 1
29 Peripheral Nervous System Agents Phase 3,Phase 1,Not Applicable
30 Analgesics Phase 3,Phase 1
31 Micronutrients Phase 3,Not Applicable
32 Vitamin B9 Phase 3,Not Applicable
33 Vitamins Phase 3,Not Applicable
34 Trace Elements Phase 3,Not Applicable
35 Folate Phase 3,Not Applicable
36 Vitamin B Complex Phase 3,Not Applicable
37
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
38
Belinostat Approved, Investigational Phase 2 866323-14-0
39
Docetaxel Approved, Investigational Phase 1, Phase 2,Phase 2 114977-28-5 148124
40
Topotecan Approved, Investigational Phase 2,Phase 1 123948-87-8, 119413-54-6 60700
41
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
42
Nivolumab Approved Phase 2 946414-94-4
43
Gemcitabine Approved Phase 2 95058-81-4 60750
44
Doxil Approved June 1999 Phase 2,Phase 1 31703
45 Antibiotics, Antitubercular Phase 2,Phase 1
46 Anti-Bacterial Agents Phase 2,Phase 1
47 Histone Deacetylase Inhibitors Phase 2
48 Protein Kinase Inhibitors Phase 2,Phase 1
49
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
50 topoisomerase I inhibitors Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
2 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
3 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
4 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
5 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
6 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
7 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
8 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
9 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
10 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
11 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
12 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
13 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
14 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
15 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
16 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
17 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
18 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
19 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
20 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
21 Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers Completed NCT00002538 Phase 2
22 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
23 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
24 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer Terminated NCT00004221 Phase 2 Carboplatin;Cyclophosphamide;Paclitaxel;Topotecan Hydrochloride
25 Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
26 Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer Terminated NCT00354601 Phase 2 capecitabine;docetaxel
27 TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed NCT01294293 Phase 1 TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
28 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
29 Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00814086 Phase 1 Paclitaxel;Cisplatin
30 Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer Completed NCT00002913 Phase 1 paclitaxel;cisplatin;topotecan hydrochloride
31 Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00079430 Phase 1 paclitaxel;carboplatin
32 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
33 Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Completed NCT00060359 Phase 1 Carboplatin;Paclitaxel Poliglumex
34 Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00006235 Phase 1 carboplatin;pegylated liposomal doxorubicin hydrochloride
35 Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer Completed NCT00002600 Phase 1 carboplatin;cyclophosphamide
36 Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003967 Phase 1 etoposide;topotecan hydrochloride
37 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer Completed NCT00005026 Phase 1 carboplatin;paclitaxel;topotecan hydrochloride
38 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
39 Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission Completed NCT00002977 Phase 1 melphalan;thiotepa
40 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
41 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
42 Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003385 Phase 1 carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride
43 TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Active, not recruiting NCT02142803 Phase 1 Sapanisertib
44 Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer Active, not recruiting NCT00357448 Phase 1
45 Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer Active, not recruiting NCT00408590 Phase 1
46 Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer Active, not recruiting NCT00652691 Phase 1 carboplatin;cyclophosphamide;topotecan hydrochloride
47 Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm Terminated NCT01525706 Phase 1 Ethanol and Paclitaxel Injection
48 Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Terminated NCT01233505 Phase 1 veliparib;capecitabine;oxaliplatin
49 Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer Terminated NCT00003380 Phase 1 etoposide;pegylated liposomal doxorubicin hydrochloride
50 Non Ivasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis Unknown status NCT02130648

Search NIH Clinical Center for Mucinous Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma, mucinous

Genetic Tests for Mucinous Cystadenocarcinoma

Anatomical Context for Mucinous Cystadenocarcinoma

MalaCards organs/tissues related to Mucinous Cystadenocarcinoma:

41
Pancreas, Ovary, Appendix, Breast, Liver, Lung, T Cells

Publications for Mucinous Cystadenocarcinoma

Articles related to Mucinous Cystadenocarcinoma:

(show top 50) (show all 260)
# Title Authors Year
1
Mucinous Cystadenocarcinoma of the Breast: Report of 2 Cases Including One With Long-Term Local Recurrence. ( 29745281 )
2018
2
Contrast-enhanced Harmonic EUS Imaging of Pancreatic Mucinous Cystadenocarcinoma. ( 29780137 )
2018
3
Mucinous cystadenocarcinoma arising from mucinous cystadenoma of the lung: case report and review of the literature. ( 29850162 )
2018
4
Appendiceal mucinous cystadenocarcinoma with mural nodules of anaplastic carcinoma and K-RAS mutation. ( 30289401 )
2018
5
Mucinous cystadenocarcinoma of the breast: the challenge of diagnosing a rare entity. ( 29081926 )
2017
6
(18)F-FDG PET/CT Imaging of Pulmonary Mucinous Cystadenocarcinoma with Signet Ring Cells. ( 28878858 )
2017
7
Pancreatic pseudocyst or mucinous cystadenocarcinoma of pancreas? A diagnostic dilemma. ( 28396777 )
2017
8
The long-term survival in primary retroperitoneal mucinous cystadenocarcinoma: a case report. ( 29177806 )
2017
9
Pseudomyxoma Peritonei as a First Manifestation of KRAS-Mutated Urachal Mucinous Cystadenocarcinoma of the Bladder: A Case Report. ( 28449606 )
2017
10
Pulmonary Mucinous Cystadenocarcinoma Presenting as Extensive Multifocal Cystic Lesions. ( 28199793 )
2017
11
Krukenberg carcinoma metastasized from stomach resembling mucinous cystadenocarcinoma of the ovary. ( 28976119 )
2017
12
Mucinous cystadenocarcinoma of ovary with metastasis in 14-year-old girl. ( 28344967 )
2017
13
Mucinous Cystadenocarcinoma in a Horse Shoe Kidney Masquerading as Giant Hydronephrosis - A Case Report: Diagnostic Challenges, Lessons Learnt and Review of Literature. ( 28050435 )
2016
14
Giant mucinous cystadenocarcinoma of ovary: A case report and review of literature. ( 27134482 )
2016
15
A giant mucinous cystadenocarcinoma of the appendix: a case report and review of the literature. ( 26945579 )
2016
16
Primary retroperitoneal mucinous cystadenocarcinoma (PRMCa): a systematic review of the literature and meta-analysis. ( 26681306 )
2016
17
Osteopathic Approach to the Diagnosis of Appendiceal Mucinous Cystadenocarcinoma Mimicking Primary Ovarian Malignant Neoplasm. ( 27367953 )
2016
18
Mature Cystic Teratoma with Co-existent Mucinous Cystadenocarcinoma in the same Ovary-A Diagnostic Dilemma. ( 28208869 )
2016
19
Primary retroperitoneal mucinous cystadenocarcinoma in a male patient. ( 27166050 )
2016
20
Mucinous cystadenocarcinoma of the pancreas with anaplastic carcinoma: A case report and review of the literature. ( 27073646 )
2016
21
Co-Existing Ovarian Mucinous Cystadenocarcinoma with Mature Cystic Teratoma: A Rare Case Report. ( 29927186 )
2016
22
Pancreatic mucinous cystadenocarcinoma: Epidemiology and outcomes. ( 27638187 )
2016
23
Radiologic Findings of Primary Mucinous Cystadenocarcinoma of the Breast: A Report of Two Cases and a Literature Review. ( 27721884 )
2016
24
Krukenberg carcinoma metastasized from stomach resembling mucinous cystadenocarcinoma of the ovary. ( 26259386 )
2015
25
A rare tumor: mucinous cystadenocarcinoma of the breast. ( 25760182 )
2015
26
Primary mucinous cystadenocarcinoma of the testis: An extremely rare ovarian-type surface epithelial carcinoma. ( 26458610 )
2015
27
Primary mucinous cystadenocarcinoma of the renal pelvis misdiagnosed as ureteropelvic junction stenosis with renal pelvis stone: a case report and literature review. ( 26612470 )
2015
28
Mucinous Cystadenocarcinoma Co-Existing with Mature Cystic Teratoma : A Rare Case Report. ( 26393136 )
2015
29
Report of a case: Retroperitoneal mucinous cystadenocarcinoma with rapid progression. ( 25884614 )
2015
30
Identification of Differentially Expressed miRNAs in Appendiceal Mucinous Cystadenocarcinoma from Mucinous Cystadenoma. ( 26807210 )
2015
31
A Case Report of Partial Nephrectomy of Mucinous Cystadenocarcinoma in Kidney and Its Literature Review. ( 25687861 )
2015
32
Mucinous cystadenocarcinoma of renal pelvis presenting as pyonephrosis. ( 24821168 )
2014
33
Misdiagnosis of pancreatic papillary mucinous cystadenocarcinoma: A case report. ( 25120659 )
2014
34
MRI, Enhanced CT, and FDG PET/CT in Primary Retroperitoneal Mucinous Cystadenocarcinoma. ( 24445275 )
2014
35
Primary retroperitoneal mucinous cystadenocarcinoma during pregnancy. ( 24832037 )
2014
36
Management of a primary retroperitoneal mucinous cystadenocarcinoma: case report. ( 24772920 )
2014
37
A 57-year-old Brazilian woman with a giant mucinous cystadenocarcinoma of the ovary: a case report. ( 24594205 )
2014
38
Primary mucinous cystadenocarcinoma of the breast with amplification of the HER2 gene confirmed by FISH - case report and review of the literature. ( 25119013 )
2014
39
Port-site metastasis after explorative laparoscopy for an incidental appendiceal mucinous cystadenocarcinoma detected with FDG PET/CT. ( 23610886 )
2013
40
Mucinous cystadenocarcinoma of the appendix in which contrast-enhanced ultrasonography was useful for assessing blood flow in a focal nodular lesion in the tumor cavity: A case report. ( 23935709 )
2013
41
A case of mucinous cystadenocarcinoma of the pancreas with spontaneous rupture diagnosed by endoscopic retrograde pancreatography. ( 23526506 )
2013
42
Mucinous cystadenocarcinoma of the appendix mimics acute appendicitis. ( 22677573 )
2013
43
Pulmonary mucinous cystadenocarcinoma: report a case and review of CT findings. ( 23483761 )
2013
44
Mucinous cystadenocarcinoma arising in an ectopic kidney simulating a retroperitoneal dermoid cyst: a rare tumour presenting as a diagnostic dilemma. ( 23817401 )
2013
45
A rare pleural mucinous cystadenocarcinoma mimicking loculated empyema initially: A case report. ( 24604931 )
2013
46
Long-term survival after hand-assisted laparoscopic approach of primary retroperitoneal mucinous cystadenocarcinoma in male: case report and review of literature. ( 23637707 )
2013
47
Pulmonary mucinous cystadenocarcinoma presenting as a pleural mesothelioma. ( 24055913 )
2013
48
Primary mucinous cystadenocarcinoma of the breast with endocervical-like mucinous epithelium. ( 24550753 )
2013
49
Primary retroperitoneal mucinous cystadenocarcinoma in a male patient: a rare case report. ( 24470741 )
2013
50
A case of Krukenberg carcinoma metastasized from colon cancer resembling mucinous cystadenocarcinoma of the ovary. ( 24427362 )
2013

Variations for Mucinous Cystadenocarcinoma

Expression for Mucinous Cystadenocarcinoma

Search GEO for disease gene expression data for Mucinous Cystadenocarcinoma.

Pathways for Mucinous Cystadenocarcinoma

GO Terms for Mucinous Cystadenocarcinoma

Cellular components related to Mucinous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.63 KRT7 MUC1 MUC16 PCNA PTPRC VIM
2 intermediate filament GO:0005882 9.13 KRT20 KRT7 VIM
3 Golgi lumen GO:0005796 8.8 MUC1 MUC16 MUC2

Biological processes related to Mucinous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament organization GO:0045109 9.16 KRT20 VIM
2 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.13 MUC1 MUC16 MUC2
3 O-glycan processing GO:0016266 8.8 MUC1 MUC16 MUC2

Sources for Mucinous Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....